Relevance of hepatitis B virus genome variability in organ transplantation

Hepatitis Monthly

Volumn 7, Issue 1, 2007, Pages 35-41

  Amini Bavil Olyaee, Samad ^a,b   Trautwein, Christian ^a   Tacke, Frank ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Hepatitis B virus; Host genetic and immune factors; Organ transplantation; Prognosis; Virus genome variability

Indexed keywords

EPITOPE; RNA DIRECTED DNA POLYMERASE;

ENZYME ACTIVITY; GENE DELETION; GENE MUTATION; GENE REPLICATION; GENE SEQUENCE; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; ORGAN TRANSPLANTATION; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; VIRUS MORPHOGENESIS;

EID: 84990301941     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Schaefer S. Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol 2007; 13: 14-21.
2. Alter MJ. Epidemiology of viral hepatitis and HIV coinfection. J Hepatol 2006; 44: S6-9.
3. Williams R. Global challenges in liver disease. Hepatology 2006; 44: 521-6.
4. Wright TL. Introduction to chronic hepatitis B infection. Am J Gastroenterol 2006; 101: S1-6.
5. Tacke F, Manns MP, Trautwein C. Influence of mutations in the hepatitis B virus genome on virus replication and drug resistance - Implications for novel antiviral strategies. Curr Med Chem 2004; 11: 2667-77.
6. Frodsham AJ. Host genetics and the outcome of hepatitis B viral infection. Transpl Immunol 2005; 14: 183-6.
7. Bruss V. Hepatitis B virus morphogenesis. World J Gastroenterol 2007; 13: 65-73.
8. Moolla N, Kew M, Arbuthnot P. Regulatory elements of hepatitis B virus transcription. J Viral Hepat 2002; 9: 323-31.
9. Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004; 24: 3-10.
10. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of hepatitis B e-antigen in patients with chronic hepatitis-B infection. Lancet 1989; 2: 588-91.
11. Kramvis A, Kew MC. The core promoter of hepatitis B virus. J Viral Hepat 1999; 6: 415-27.
12. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol 2005; 32: 102-12.
13. Zuckerman AJ. Effect of hepatitis B virus mutants on efficacy of vaccination. Lancet 2000; 355: 1382-4.
14. Chevaliez S, Challine D, Rigot P, et al. Role of HBs antigen (HBsAg) mutants in the lack of detection of hepatitis B virus infection in organ, tissue and cell transplant donors. Hepatology 2005; 42: 489A-90A.
15. Locarnini S. Molecular virology and the development of resistant mutants: Implications for therapy. Semin Liver Dis 2005; 25: 9-19.
16. Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006; 78: S52-5.
17. Bartholorneusz A, Locarnini SA. Antiviral drug resistance: Clinical consequences and molecular aspects. Semin Liver Dis 2006; 26: 162-70.
18. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131: 1253-61.
19. Yim HJ, Lok ASF. Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. Hepatology 2006; 43: S173-81.
20. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Ann Rev Immunol 1995; 13: 29-60.
21. Baumert TF, Thimme R, von Weizsacker F. Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007; 13: 82-90.
22. Fabrizi F, Bunnapradist S, Martin P. HBV infection in patients with end-stage renal disease. Semin Liver Dis 2004; 24: 63-70.
23. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-63.
24. Wu LM, Xu X, Zheng SS. Hepatitis B virus reinfection after liver transplantation: related risk factors and perspective. Hepatobiliary Pancreat Dis Int 2005; 4: 502-8.
25. Gish RG, McCashland T. Hepatitis B in liver transplant recipients. Liver Transpl 2006; 12: S54-64.
26. Gunther S, Piwon N, Iwanska A, et al. Type, prevalence, and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease. J Virol 1996; 70: 8318-31.
27. Gunther S, Baginski S, Kissel H, Reinke P, Kruger DH, Will H, et al. Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease. Hepatology 1996; 24: 751-8.
28. Carman WF, Trautwein C, vanDeursen FJ, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24: 489-93.
29. Trautwein C, Schrem H, Tillman HL, et al. Hepatitis B virus mutations in the pre-S genome before and after liver transplantation. Hepatology 1996; 24: 482-8.
30. Gunther S, Piwon N, Jung A, et al. Enhanced replication contributes to enrichment of hepatitis B virus with a deletion in the core gene. Virology 2000; 273: 286-99.
31. Bock CT, Buerke B, Tillmann HL, et al. Relevance of hepatitis B core gene deletions in patients after kidney transplantation. Gastroenterology 2003; 124: 1809-20.
32. Trautwein C. Mechanisms of hepatitis B virus graft reinfection and graft damage after liver transplantation. J Hepatol 2004; 41: 362-9.
33. Meisel H, Preikschat P, Reinke P, et al. Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine. Transpl Int 1999; 12: 283-7.
34. Tacke F, Gehrke C, Luedde T, et al. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of lamivudine-resistant mutants. J Virol 2004; 78: 8524-35.
35. Alexopoulou A, Dourakis SP. Genetic heterogeneity of hepatitis viruses and its clinical significance. Curr Drug Targets Inflamm Allergy 2005; 4: 47-55.
36. Angus PW, Locarnini SA, Mccaughan GW, et al. Hepatitis-B virus precore mutant infection is associated with severe recurrent disease after liver-transplantation. Hepatology 1995; 21: 14-8.
37. Mcmillan JS, Bowden DS, Angus PW, Mccaughan GW, Locarnini SA. Mutations in the hepatitis B virus precore/core gene and core promoter in patients with seven: Recurrent disease following liver transplantation. Hepatology 1996; 24: 1371-8.
38. Mcivor C, Morton J, Bryant A, et al. Fatal reactivation of precore mutant hepatitis-B virus-associated with fibrosing cholestatic hepatitis after bone-marrow transplantation. Ann Intern Med 1994; 121: 274-5.
39. Tanaka S, Yoshiba M, Iino S, et al. A common-source outbreak of fulminant-hepatitis-B in hemodialysis-patients induced by precore mutant. Kidney Int 1995; 48: 1972-8.
40. Sterneck M, Gunther S, Gerlach J, et al. Serial analysis of the complete hepatitis B virus nucleotide sequences in patients with recurrent fulminant hepatitis after liver transplantation. Hepatology 1996; 24: 638.
41. Sterneck M, Gunther S, Gerlach J, et al. Hepatitis B virus sequence changes evolving in liver transplant recipients with fulminant hepatitis. J Hepatol 1997; 26: 754-64.
42. Stuyver L, De Gendt S, Cadranel JF, et al. Three cases of severe subfulminant hepatitis in heart-transplanted patients after nosocomial transmission of a mutant hepatitis B virus. Hepatology 1999; 29: 1876-83.
43. Chen PM, Yao NS, Wu CM, et al. Detection of reactivation and genetic mutations of the hepatitis B virus in patients with chronic hepatitis B infections receiving hematopoietic stem cell transplantation. Transplantation 2002; 74: 182-8.
44. Harrison TJ. Hepatitis B virus. Molecular virology and common mutants. Semin Liver Dis 2006; 26: 87-96.
45. Gerolami R, Henry M, Borentain P, et al. Fulminant hepatitis B associated with a specific insertion in the basal core promoter region of hepatitis B virus DNA after immunosuppressive treatment. Clin Infect Dis 2005; 40: E24-7.
46. Zampino R, Marrone A, Ragone E, et al. Heart transplantation in patients with chronic hepatitis B: Clinical evolution, molecular analysis, and effect of treatment. Transplantation 2005; 80: 1340-3.
47. Reinke P, Baginski S, Gunther S, et al. Association between the accumulation of hepatitis B virus core gene deletion mutants and progression of liver disease in longterm renal transplant patients. Transplant Proc 1997; 29: 815-6.
48. Preikschat P, Meisel H, Will H, Gunther S. Hepatitis B virus genomes from long-term immunosuppressed virus carriers are modified by specific mutations in several regions. J Gen Virol 1999; 80: 2685-91.
49. Preikschat P, Gunther S, Reinhold S, et al. Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. Hepatology 2002; 35: 466-77.
50. Ghany MG, Ayola B, Villamil FG, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27: 213-22.
51. Seddigh-Tonekaboni S, Waters JA, Jeffers S, et al. Effect of variation in the common “a” determinant on the antigenicity of hepatitis B surface antigen. J Med Virol 2000; 60: 113-21.
52. Delaney WE, Edwards R, Colledge D, et al. Crossresistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drugresistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001; 45: 1705-13.
53. Marschenz S, Endres AS, Brinckmann A, et al. Functional analysis of complex hepatitis B virus variants associated with development of liver cirrhosis. Gastroenterology 2006; 131: 765-80.
54. Turkaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis-B virus-DNA contains a glucocorticoid-responsive element. Proceedings of the National Academy of Sciences of the United States of America 1986; 83: 1627-31.
55. Turkaspa R, Shaul Y, Moore DD, et al. The glucocorticoid receptor recognizes a specific nucleotide-sequence in hepatitis-B virus-DNA causing increased activity of the HBV enhancer. Virology 1988; 167: 630-3.
56. Visvanathan K, Lewin SR. Immunopathogenesis: Role of innate and adaptive immune responses. Semin Liver Dis 2006; 26: 104-15.
57. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-29.
58. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: Mechanisms, detection and interpretation. J Hepatol 2006; 44: 593-606.
59. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44: 1656-65.
60. Zoulim F. Hepatitis B virus resistance to entecavir in nucleoside naive patients: Does it exist? Hepatology 2006; 44: 1404-7.